Author

Axel Dignass

The UEG Week Premiere
The UEG Week Premiere

Axel Dignass

THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS THROUGH WEEK 12
THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS THROUGH WEEK 12

Good Morning UEG Week
Good Morning UEG Week

Axel Dignass  et al.

European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases
European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases

Axel Dignass  et al.

SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL
SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL

OZANIMOD EFFICACY BY BASELINE ENDOSCOPIC DISEASE DISTRIBUTION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A POST HOC ANALYSIS FROM TRUE NORTH
OZANIMOD EFFICACY BY BASELINE ENDOSCOPIC DISEASE DISTRIBUTION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A POST HOC ANALYSIS FROM TRUE NORTH

SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL
SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL

Axel Dignass  et al.

Words of welcome
Words of welcome

Axel Dignass  et al.

The UEG Week Premiere
The UEG Week Premiere

Axel Dignass  et al.

HEALTHCARE RESOURCE UTILIZATION AND TREATMENT USAGE AMONG FLARING AND NON-FLARING PATIENTS WITH ULCERATIVE COLITIS – A REAL-WORLD GLOBAL STUDY
HEALTHCARE RESOURCE UTILIZATION AND TREATMENT USAGE AMONG FLARING AND NON-FLARING PATIENTS WITH ULCERATIVE COLITIS – A REAL-WORLD GLOBAL STUDY

Axel Dignass  et al.

HIGH PROPORTION OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE SHOW SIGNS OF RELEVANT DISEASE ACTIVITY – RESULTS FROM THE GERMAN COHORT OF THE IBD PODCAST STUDY
HIGH PROPORTION OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE SHOW SIGNS OF RELEVANT DISEASE ACTIVITY – RESULTS FROM THE GERMAN COHORT OF THE IBD PODCAST STUDY

Axel Dignass  et al.

Assessing ulcerative colitis: Is there something your patient isn’t telling you? (Eli Lilly and Company)
Assessing ulcerative colitis: Is there something your patient isn’t telling you? (Eli Lilly and Company)

Axel Dignass  et al.

Avant-garde treatment approaches in IBD management: targeting the IL-23 pathway (Janssen)
Avant-garde treatment approaches in IBD management: targeting the IL-23 pathway (Janssen)

Axel Dignass  et al.

UEG Week Virtual: Words of welcome
UEG Week Virtual: Words of welcome

Axel Dignass  et al.

OZANIMOD EFFICACY BY BASELINE ENDOSCOPIC DISEASE DISTRIBUTION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A POST HOC ANALYSIS FROM TRUE NORTH
OZANIMOD EFFICACY BY BASELINE ENDOSCOPIC DISEASE DISTRIBUTION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A POST HOC ANALYSIS FROM TRUE NORTH

Axel Dignass  et al.

Navigating Experience and Possibilities with Subcutaneous Infliximab as a Biobetter in IBD (Celltrion Healthcare)
Navigating Experience and Possibilities with Subcutaneous Infliximab as a Biobetter in IBD (Celltrion Healthcare)

Axel Dignass  et al.

Bringing light to patient centric goals in UC: the LUCENT results (Eli Lilly and Company) (Complete Session)
Bringing light to patient centric goals in UC: the LUCENT results (Eli Lilly and Company) (Complete Session)

Axel Dignass  et al.

THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS THROUGH WEEK 12
THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS THROUGH WEEK 12

Axel Dignass  et al.

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

Axel Dignass  et al.

CHARACTERISTICS OF FILGOTINIB-TREATED PATIENTS WITH ULCERATIVE COLITIS WHO ACHIEVE SUSTAINED CORTICOSTEROID-FREE REMISSION: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY
CHARACTERISTICS OF FILGOTINIB-TREATED PATIENTS WITH ULCERATIVE COLITIS WHO ACHIEVE SUSTAINED CORTICOSTEROID-FREE REMISSION: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

Axel Dignass  et al.

Item 1 - 20 / 44
1
2 3